Solvent extraction of urine analyzed by GC-MS and XGBoost distinguished bladder cancer patients from controls with AUROC 0.869 and 85% balanced sensitivity and specificity using an 8-metabolite panel.
On 2026-08-07, researchers reported a urine-based test for urothelial bladder cancer that combines solvent extraction, GC-MS profiling, and machine learning. In 100 participants, an XGBoost model using an 8-metabolite panel achieved AUROC 0.869, improving on classical statistics at 0.752, with 85% balanced sensitivity and specificity.
- Impact 30%
- 69
- Evidence 25%
- 95
- Scale 20%
- 35
- Confidence 15%
- 87
- Recency 10%
- 88
Updated Aug 10, 2026 · TRV-2026-0728
ace